Emma Tallantyre

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): A mixed‑methods, multi‑centre feasibility randomised controlled trial

Roshan das Nair (8051357), Gogem Topcu, Nia Goulden, Shaun Harris et autres

Background: Cognitive difficulties are common in people with multiple sclerosis (pwMS), yet access to neuropsychological rehabilitation is often limited or only provided to those with more severe impairments. The NEuRoMS intervention provides brief, tailored neuropsychological rehabilitation for pwMS with mild-to-moderate cognitive difficulties. …

Multiple Sclerosis and ethnicity in Wales: a SAIL Databank study

James Witts, Emma Tallantyre, Jeff Rodgers, R Nicholas et autres

Introduction: Multiple Sclerosis (MS) is the commonest non-traumatic cause of disability in younger people. Prevalence of MS by deprivation and ethnicity is rarely reported, as ethnicity is not accurately or consistently recorded in national datasets. Ethnicity data within the Secure Anonymised Information …

gb (code pays fourni par la source)

Defining Activity‐Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal

Catalina Lopez Manzano, Claire M Rice, Emma Tallantyre, Chris Cooper et autres

BACKGROUND: Multiple sclerosis (MS) is commonly stratified into activity-based subgroups to inform treatment decisions and health technology assessments (HTAs). However, the terminology and criteria used to define these subgroups, particularly 'active', 'highly active' and 'rapidly evolving severe' (RES) disease, are inconsistent across …

gb (code pays fourni par la source)

Non-invasive biomarkers for Neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis

Tarunya Arun, W. John Watkins, Kirsten Baillie, Sam Loveless et autres

gb (code pays fourni par la source)

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study

Gavin Giovannoni, Gavin Giovannoni, Laura Airas, Riley Bove et autres

BACKGROUND: The ORATORIO trial showed that ocrelizumab reduced the risk of disability progression versus placebo in patients with primary progressive multiple sclerosis (PPMS). We aimed to elucidate the effect of ocrelizumab in older and more disabled patients with PPMS, particularly regarding hand …

gb, fi, us, pl, rs, ch, es, ca (code pays fourni par la source)

Multi-arm multi-stage platform trials for neurological disease: accelerating progress

Paresh Malhotra, Suvankar Pal, Emma Tallantyre, Thomas Foltynie et autres

gb, us (code pays fourni par la source)

Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial

Thomas Williams, Nicholas Magill, Nevin John, Alessia Bianchi et autres

Vascular comorbidity is associated with more severe disability in multiple sclerosis. However, it is unknown whether treating vascular risk will lead to a disease modifying effect. Given the established role of simvastatin as a modifier of vascular risk, we aimed to investigate …

gb, au, us, es, it, nl (code pays fourni par la source)

Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): A mixed-methods, multi-centre feasibility randomised controlled trial

Roshan das Nair, Gogem Topcu, Nia Goulden, Shaun Harris et autres

Background: Cognitive difficulties are common in people with multiple sclerosis (pwMS), yet access to neuropsychological rehabilitation is often limited or only provided to those with more severe impairments. The NEuRoMS intervention provides brief, tailored neuropsychological rehabilitation for pwMS with mild-to-moderate cognitive difficulties. …